Skip to main content
Premium Trial:

Request an Annual Quote

CTC Dx Firm Biocept Goes Public at $10 per Share

NEW YORK (GenomeWeb News) – Biocept today went public as shares of its common stock began trading at $10, the low end of an anticipated price range on its initial public offering.

In afternoon trading, the company's shares, which trade under ticker symbol "BIOC" on the Nasdaq, were down 6 percent at $9.39.

The San Diego-based oncology diagnostics firm offered 1.9 million shares of its common stock as part of its IPO, which is expected to bring in $19 million in gross proceeds. The offering is expected to close on Feb. 10.

Aegis Capital and Feltl and Co. are joint book-running agents. Biocept has granted the underwriters a 45-day option to purchase up to 285,000 additional shares of common stock to cover any overallotments.

Biocept filed for its IPO in September and later said that it expected to fetch between $10 and $12 per share in its offering.

Founded in 1997, Biocept operates a CLIA-certified and CAP-accredited laboratory. It develops and commercializes cancer diagnostics based on CTCs and circulating tumor DNA tests designed to help physicians choose the most appropriate treatments for their patients.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.